Wednesday, 20 Nov 2019

PsA/SpA

Datesort ascending Type Title Save
12 Nov 2019 Social Dr Atul Deodhar wows the crowd at #ACR19 showing abtract #2729 Ixekizumab in Non-Radiographic Axial Spondyloarthritis: Phase 3 Trial showing IXE is effective by ASAS40. https://t.co/Bcb20FYNoH
12 Nov 2019 Social RT @EBRheum: #ACR19 Abst#2728 Plenary: Upadacitinib RCT in AnkSpa Improved ASAS40 at wk14 (52% v 26% PLBO, NNT~4) and SPARCC MRI Scores.…
12 Nov 2019 Social RT @_connectedcare: Upadacitinib in AS Nice to the rapid response #ACR19 @rheumnow Abst2728 https://t.co/woAZbdb5QY
12 Nov 2019 Social RT @_connectedcare: Upadacitinib in AS And here’s the Safety Slide #ACR19 @rheumnow Abst2728 https://t.co/fpjhrjGp0N
12 Nov 2019 Social RT @_connectedcare: EAMs: I know there's published data but among Axial SpA patients you actually see, what is the most common EAM? @rheum…
12 Nov 2019 Social RT @philipcrobinson: Use of complementary and alternative medicines in #psoriatic arthritis Abs 2462 #ACR19 @RheumNow https://t.co/h8UTbOwW…
12 Nov 2019 ACR Video Domain Strategy and Treatment in Psoriatic Arthritis: Dr. Elaine Husni
12 Nov 2019 ACR Video Depression in Psoriatic Arthritis: Dr. Olga Petryna
12 Nov 2019 Social RT @DrPetryna: #ACR19 @rheumnow ABS2439 retrospective cohort study of PSA +HUC/gout shows HUC independently associated w/CVD, mainly w/ Afi…
12 Nov 2019 Social RT @philipcrobinson: My write-up of data on IL-17 Inhibitors In Non-Radiographic Axial SpA presented here at #ACR19 @rheumnow https://t.co/…
12 Nov 2019 Social RT @_connectedcare: Bullish on value of Polygenic Risk scores to help diagnose Axial SpA (not commercially available yet) #ACR19 @rheumnow…
11 Nov 2019 Social RT @_connectedcare: Do you agree there is so much IBD in our SpA patients? #ACR19 @rheumnow 4M064 https://t.co/0IDujdyZdu
11 Nov 2019 Social RT @EBRheum: RCT Tildrakizumab (IL23i) in Psoriatic Arthritis Beat PLBO for ACR20 (NNT~4), ACR50 (NNT~4), and pt global (NNT~3 for 50% imp…
11 Nov 2019 Social RT @synovialjoints: Continued Ixekizumab was superior to PBO in maintaining MDA in biologic-naïve PsA pts who achieved sustained MDA on ini…
11 Nov 2019 Social RT @MaeveGamble: If 50% of SpA pts have microscopic bowel disease, 10% have clinically significant bowel disease...should all patients diag…
11 Nov 2019 Social RT @philipcrobinson: Exciting phase 2 data on bimekizumab (dual anti-17A and F) in r-axSpA, looks like 160mg is the go, I hear on the grape…
11 Nov 2019 Social RT @DrPetryna: #ACR19 @rheumnow ABS1513 Tofacitinib efficacy in PSA ⬇️ if BL BMI ≥ 35 . Safety consistent across all BL BMI categories. 3 C…
11 Nov 2019 Social RT @DrPetryna: #ACR19 @rheumnow abs1913 Cohort study confirms the association of HLA-B*15 with peripheral joint involvement in AS but not i…
11 Nov 2019 Social RT @philipcrobinson: Nice data in r-axSpA treated with ixekizumab showing improvements in fatigue, pain and sleep #ACR19 @RheumNow Abs 1510…
11 Nov 2019 Social RT @EBRheum: Abst#1501 - 52w data for IXE in AxSpa, #ACR19 @RheumNow Take open label follow up with a grain of salt, but good to see pers…